(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy. CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE